اهمیت بررسی ناپایداری‌های ژنومی در درمان‌های مبتنی بر سلو‌ل‌های بنیادی

نوع مقاله : مقاله مروری

نویسندگان

استادیار، مرکز تحقیقات سلولی و مولکولی، دانشگاه علوم پزشکی شهرکرد، شهرکرد، ایران

چکیده

سلول‌های بنیادی، جزء اصلی درمان‌های مبتنی بر سلول و پزشکی بازساختی، جهت جایگزینی بافت‌ها و اعضای آسیب دیده و درمان بیماری‌های مختلف هستند. تکثیر و تمایز سلول‌های بنیادی، جهت استفاده در پزشکی بازساختی، مستلزم کشت این سلول‌ها به صورت In vitro است. هر چند تا کنون خطرزا بودن استفاده از این سلول‌ها اثبات نشده است، اما علاوه بر احتمال وجود سلول‌های تمایز نیافته و تمایز خودبه‌خودی آن‌ها پس از پیوند و ایجاد تراتوما، ژنوم این سلول‌ها در محیط‌های کشت، بی‌ثبات است و تغییر می‌کند. ناپایداری ژنومی، می‌تواند ایمنی پیوند این سلول‌ها یا بافت‌های حاصل از آن‌ها را با چالش روبه‌رو کند. ناپایداری ژنومی، از ویژگی‌های مشترک سلول‌های سرطانی و بنیادی است. از این رو، این نگرانی وجود دارد که ناپایداری ژنومی در سلول‌های بنیادی، تومورزا باشد. ناپایداری‌های ژنومی، در اندازه‌های مختلف از جهش نقطه‌ای تا آنیوپلوئیدی و موزاییسم را شامل می‌شود. نوع سلول بنیادی، برخی شرایط محیط کشت و نحوه‌ی دست‌ورزی سلول‌ها، از جمله زمان طولانی کشت، در ایجاد و فراوانی این ناپایداری‌ها مؤثر است. از این رو، توصیه می‌شود ضمن بهینه نمودن زمان و شرایط کشت، قبل از استفاده‌های درمانی، وجود احتمالی تغییرات ژنومی با روش‌های آشکارسازی مناسب، بررسی و پی‌گیری شود.

کلیدواژه‌ها

عنوان مقاله [English]

Importance of Analyzing the Genomic Instability in Stem Cell-Based Therapies

نویسندگان [English]

  • Akram Alizadeh
  • Sorayya Ghasemi
Assistant Professor, Cellular and Molecular Research Center, Shahrekord University of Medical sciences, Shahrekord, Iran
چکیده [English]

Stem cells are the main component in cell-based therapies and regenerative medicine to replace damaged tissues and cure various diseases. In regenerative medicine, in vitro stem cells’ culture is required for proliferation and differentiation. Although the risk of using these cells has not been established; but in addition to the possibility of spontaneous differentiation of undifferentiated cells after transplantation and teratoma formation, genome of these cells in culture media is instable and can be changed. Genomic instability can affect the transplantation safety of these cells or tissues derived from them. Genomic instability is one of the common features in stem cells and cancer. Hence, there is concern that the genomic instability during the manipulation of stem cells can be tumorigenic. Genomic instabilities are included in different sizes from point mutation to aneuploidy and mosaicism. Types of stem cells, culture conditions and some manipulation of cells such a long time are effective in creation and the rate of these instabilities. Therefore, in addition to optimizing the time and culture conditions, it is recommended to examine and follow the genomic abnormalities before therapeutic uses with appropriate methods.

کلیدواژه‌ها [English]

  • Genomic instability
  • Stem cells
  • Cell-based therapy

مراجع

  1. Alizadeh A, Tarihi T, Dashtnavard H. The Influence of lithium chloride on induction of bone marrow stromal cells into neuronal phenotype. Daneshvar Med 2009; 16(79); 51-6. [In Persian].
  2. Eftekharzadeh M, Nobakht M, Alizadeh A, Soleimani M, Hajghasem M, Kordestani SB, et al. The effect of intrathecal delivery of bone marrow stromal cells on hippocampal neurons in rat model of Alzheimer's disease. Iran J Basic Med Sci 2015; 18(5): 520-5.
  3. Martins-Taylor K, Xu RH. Concise review: Genomic stability of human induced pluripotent stem cells. Stem Cells 2012; 30(1): 22-7.
  4. Golipoor Z, Mehraein F, Zafari F, Alizadeh A, Ababzadeh S, Baazm M. Migration of Bone Marrow-Derived Very Small Embryonic-Like Stem Cells toward An Injured Spinal Cord. Cell J 2016; 17(4): 639-47.
  5. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007; 213(2): 341-7.
  6. Alizadeh A, Soleimani M, Ai J, Fallah A, Hashemian SJ, et al. Lentiviral mediated overexpression of NGF in adipose-derived stem cells. Clon Transgen 2015; 4(3): 142.
  7. Bakhshayesh M, Soleimani M, Mehdizadeh M, Katebi M. Effects of TGF-beta and b-FGF on the potential of peripheral blood-borne stem cells and bone marrow-derived stem cells in wound healing in a murine model. Inflammation 2012; 35(1): 138-42.
  8. Tarahani Nia M, Alizadeh A, Takhshid MA, Sadroddiny E. Decellularization of lung tissue and analysis of its differentiative potential on bone marrow mesenchymal stem cells of rat. Appl Tissue Eng 2015; 2(1): 1-11.
  9. Mitalipova MM, Rao RR, Hoyer DM, Johnson JA, Meisner LF, Jones KL, et al. Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol 2005; 23(1): 19-20.
  10. Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, Zucker JP, et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 2004; 350(13): 1353-6.
  11. Lund RJ, Narva E, Lahesmaa R. Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet 2012; 13(10): 732-44.
  12. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7(4): 521-31.
  13. Ghasemi S, Mozdarani H, Soleimani M. The Effect of miR-372 on genome instability in MKN-45 cell line. J Isfahan Med Sch 2015; 32(311): 2035-47.
  14. Peterson SE, Loring JF. Genomic instability in pluripotent stem cells: implications for clinical applications. J Biol Chem 2014; 289(8): 4578-84.
  15. Lefort N, Perrier AL, Laabi Y, Varela C, Peschanski M. Human embryonic stem cells and genomic instability. Regen Med 2009; 4(6): 899-909.
  16. Seminatore C, Polentes J, Ellman D, Kozubenko N, Itier V, Tine S, et al. The postischemic environment differentially impacts teratoma or tumor formation after transplantation of human embryonic stem cell-derived neural progenitors. Stroke 2010; 41(1): 153-9.
  17. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40(5): 499-507.
  18. Yang S, Lin G, Tan YQ, Zhou D, Deng LY, Cheng DH, et al. Tumor progression of culture-adapted human embryonic stem cells during long-term culture. Genes Chromosomes Cancer 2008; 47(8): 665-79.
  19. Ballabeni A, Park IH, Zhao R, Wang W, Lerou PH, Daley GQ, et al. Cell cycle adaptations of embryonic stem cells. Proc Natl Acad Sci USA 2011; 108(48): 19252-7.
  20. Varela C, Denis JA, Polentes J, Feyeux M, Aubert S, Champon B, et al. Recurrent genomic instability of chromosome 1q in neural derivatives of human embryonic stem cells. J Clin Invest 2012; 122(2): 569-74.
  21. Weissbein U, Benvenisty N, Ben-David U. Quality control: Genome maintenance in pluripotent stem cells. J Cell Biol 2014; 204(2): 153-63.
  22. Liang Q, Conte N, Skarnes WC, Bradley A. Extensive genomic copy number variation in embryonic stem cells. Proc Natl Acad Sci USA 2008; 105(45): 17453-6.
  23. Nguyen HT, Geens M, Mertzanidou A, Jacobs K, Heirman C, Breckpot K, et al. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. Mol Hum Reprod 2014; 20(2): 168-77.
  24. Taapken SM, Nisler BS, Newton MA, Sampsell-Barron TL, Leonhard KA, McIntire EM, et al. Karyotypic abnormalities in human induced pluripotent stem cells and embryonic stem cells. Nat Biotech 2011; 29(4): 313-4.
  25. Avery S, Hirst AJ, Baker D, Lim CY, Alagaratnam S, Skotheim RI, et al. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Reports 2013; 1(5): 379-86.
  26. Werbowetski-Ogilvie TE, Morrison LC, Fiebig-Comyn A, Bhatia M. In vivo generation of neural tumors from neoplastic pluripotent stem cells models early human pediatric brain tumor formation. Stem Cells 2012; 30(3): 392-404.
  27. Wang Y, Han ZB, Song YP, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int 2012; 2012: 652034.
  28. Ku S, Soragni E, Campau E, Thomas EA, Altun G, Laurent LC, et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAATTC triplet repeat instability. Cell Stem Cell 2010; 7(5): 631-7.
  29. Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One 2011; 6(10): e26203.
  30. Devys D, Biancalana V, Rousseau F, Boue J, Mandel JL, Oberle I. Analysis of full fragile X mutations in fetal tissues and monozygotic twins indicate that abnormal methylation and somatic heterogeneity are established early in development. Am J Med Genet 1992; 43(1-2): 208-16.
  31. Li LB, Chang KH, Wang PR, Hirata RK, Papayannopoulou T, Russell DW. Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 2012; 11(5): 615-9.
  32. Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A 2012; 109(43): 17567-72.
  33. Afonso CD, Batistuzzo de Medeiros SR. Genetic evaluation of mesenchymal stem cells. Rev Bras Hematol Hemoter 2014; 36(4): 238-40.
  34. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011; 9(2): 97-102.
  35. Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010; 115(8): 1549-53.
  36. Borgonovo T, Vaz IM, Senegaglia AC, Rebelatto CL, Brofman PR. Genetic evaluation of mesenchymal stem cells by G-banded karyotyping in a Cell Technology Center. Rev Bras Hematol Hemoter 2014; 36(3): 202-7.
  37. Ren Z, Wang J, Zhu W, Guan Y, Zou C, Chen Z, et al. Spontaneous transformation of adult mesenchymal stem cells from cynomolgus macaques in vitro. Exp Cell Res 2011; 317(20): 2950-7.
  38. Serakinci N, Fahrioglu U, Christensen R. Mesenchymal stem cells, cancer challenges and new directions. Eur J Cancer 2014; 50(8): 1522-30.
  39. Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011; 29(12): 1132-44.
  40. Jacobs K, Zambelli F, Mertzanidou A, Smolders I, Geens M, Nguyen HT, et al. Higher-Density Culture in Human Embryonic Stem Cells Results in DNA Damage and Genome Instability. Stem Cell Reports 2016; 6(3): 330-41.
  41. Herberts CA, Kwa MS, Hermsen HP. Risk factors in the development of stem cell therapy. J Transl Med 2011; 9: 29.
  42. Peterson SE, Westra JW, Rehen SK, Young H, Bushman DM, Paczkowski CM, et al. Normal human pluripotent stem cell lines exhibit pervasive mosaic aneuploidy. PLoS One 2011; 6(8): e23018.
  43. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, et al. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010; 285(7): 4931-40.
  44. Catalina P, Cobo F, Cortes JL, Nieto AI, Cabrera C, Montes R, et al. Conventional and molecular cytogenetic diagnostic methods in stem cell research: a concise review. Cell Biol Int 2007; 31(9): 861-9.
مجله دانشکده پزشکی اصفهان
دوره 34، شماره 383 - شماره پیاپی 383
مرداد و شهریور 1395
صفحه 572-579

فایل ها

سابقه مقاله

  • تاریخ دریافت: 28 اردیبهشت 1395
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار